The NHS in England is set to roll out the immunotherapy pill cladribine, allowing thousands of multiple sclerosis patients to manage their treatment at home. This major development, approved by NICE, eliminates the need for regular hospital visits and extensive monitoring, impacting particularly younger women who commonly face MS diagnosis. The treatment requires only 20 doses over four years, reducing healthcare burdens and potentially enabling patients to safely conceive while on medication. This innovative approach is seen as a significant advancement for those with active relapsing-remitting MS in Europe.
Klaus Schmierer, professor of neurology, highlights that this decision opens up access to a treatment that minimally interferes with patients’ daily lives and routines.
Cladribine offers a new treatment option, allowing MS patients to take immunotherapy at home with a reduced schedule of only 20 doses over four years.
Collection
[
|
...
]